At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Haematol
Auteurs principaux: Ganzel, Chezi, Wang, Xin V., Rowe, Jacob M., Richards, Susan M., Buck, Georgina, Marks, David I., Litzow, Mark R., Paietta, Elisabeth M., Foroni, Letizia, Luger, Selina M., Willman, Cheryl L., Mullighan, Charles G., Roberts, Kathryn G., Wiernik, Peter H., Douer, Dan, Lazarus, Hillard M., Tallman, Martin S., Goldstone, Anthony H.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Haematological Malignancy – Clinical
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7687130/
https://ncbi.nlm.nih.gov/pubmed/32220069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16616
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires